Icon times
Cipla Stock Fundamental Analysis - Financial Results & Equity Research | Investyadnya Stock-o-Meter

Cipla

CompanyOver

 / 
 
 

About

Cipla is a company which was discovered in 1935 by late Dr. K.A. Hamied and is currently spearheaded by Dr. Y. K. Hamied. The company has more than 80 years of experience in the Pharma Industry. The company is engaged in manufacturing of Formulations and Active Pharmaceutical Ingredients (APIs). The company has vast presence in India, South Africa,North America, regulated as well as emerging markets. Cipla supplies branded and generic medicines to over 170 countries globally.

Highlights

Performing rate for the company

Price Chart (Only Standalone)

Track the companies of Group.

Relaince Group

Sector: Refineries

Market Price

2,529.50

Market Cap(₹Cr.)

2,529.50

-90.00

Quarterly Results ( Figures in Rs. Crores.)

No Data is available.

Profit & Loss ( Figures in Rs. Crores.)

No Data is available.

Balance Sheet ( Figures in Rs. Crores.)

No Data is available.

Cash Flows ( Figures in Rs. Crores.)

No Data is available.

Historical Growths

Compounded Sales Growth
Compounded Profit Growth
Compounded Expense Growth
Stock Price CAGR
Sales Growth Profit Growth Expense Growth Stock Price CAGR

Ratios ()

No Data is available.

Major Shareholders

No Data is available.

Shareholders more than 1%

No Data is available.

Fund houses invested in the stock (Figures in % Equity Capital )

No Data is available.

Corporate Action

No Data is available.
No Data is available.
No Data is available.
No Data is available.

Documents

Presentation & Earning Calls

Annual Reports

Credit Rating

No document is available
No document is available
No document is available
No document is available.

Overview

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Products

Generics and branded generics
Specialty
Consumer health
Awards:
2013:
Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.
2014
Cipla won the Global L&D Team of the Year Award
Brand, Azee bagged the Marketing Excellence Award in 2014
Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs
2015:
Won the Award for Excellence in Rural Reach at India Pharma Awards
Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015
2016:
The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners
2017:

Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017
2018:

India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
Indian Digital Awards (IDA) for Excellence in Digital Publishing
ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets
2019:

Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019
2020:

Cipla Sri Lanka is Great Place to Work Certified
Cipla is Great Place to Work Certified
‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report
Milestones
1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.

Cipla was founded as The Chemical, Industrial, & Pharmaceutical Laboratories by Khwaja Abdul Hamied in 1935. It is a market-leading renowned medicine producer in India. The company has approximately 2,000 pharmaceutical products in more than 60 therapeutic categories. With their motto as caring for life, the drugs are sold domestically, while others reach global markets in more than 170 nations. They brought a revolution when it comes to affordable medicines and pharmaceuticals in India and abroad. Cipla leads the domestic retail pharmaceutical market. It has eight manufacturing plants located throughout the country. With their net income standing robust at a whopping 220 million USD, CIPLA markets as the 42nd largest publicly traded company by India’s market value. What makes it even better is that it is the world's largest drug manufacturer to fight HIV-AIDS. Equity shares of CIPLA are listed in the Bombay stock exchange, India’s National stock exchange, and the Luxembourg Stock Exchange.


SERVICES

Cipla has over 2,000 products in 65 therapeutic categories.

It gives prescription medicines for every sort of disease -- arthritis, cancer, depression -- as well as the staple meds for colds, oral hygiene, and skincare. 


The firm also makes bulk drugs, agrochemicals, and animal products. 
They manufacture antiretroviral drugs for HIV-AIDS.
They also deal in anti-depressants, and steroids like Fluticasone propionate, to treat asthma and other such ailments.
CIPLA deals in active pharmaceutical ingredients with other manufacturers as well.
They also cooperate with other enterprises in consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

MERGERS AND ACQUISITIONS
In 2018 CIPLA bought US-based pharmaceutical Avenue Therapeutics for as much as 215 million USD.
In 2016 CIPLA joined itself with two other US-based pharmaceutical forces named InvaGen Pharmaceuticals and Exelan Pharmaceuticals to expand its reach in the United States.
In 2015 Cipla started a joint venture with Cooper Pharma and The Pharmaceutical Institute. It will focus on respiratory and neurology products.
2020 Cipla and Stempeutics collaborate for the launch of Stempeucel, the first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI).
MILESTONES
1960-CIPLA commercialises the technology to extract diosgenin from Dioscorea tubers for the first time in India.
1968-turnover crosses the 1CR mark.
1972- Changing the patent law to bring affordable pharma in India. 
1991- turnover crosses Rs. 100 crores
2000- launched a range of CFC-free metered dose inhalers and the world’s first CFC-free budesonide inhaler.
2001- In a paradigm-changing move, Cipla offers a triple AntiRetroViral cocktail to Médecins Sans Frontières (MSF) for $350/patient/year to battle HIV/AIDS. A drug helping patients with HIV costing less than a dollar per day.
2017-Launch of Cipla SAGA (Sub-Saharan Africa and Global Access)
2020- Favipiravir is an oral antiviral drug for clinical recovery in COVID -19 patients with mild to moderate symptoms
ACHIEVEMENTS
In 1980, Cipla won the Chemexcil Award for Excellence for exports.
In 2005 Dr Y.K. Hamied wins the coveted Padma Bhushan Award by the late President of India, Dr A. P. J. Abdul Kalam.
Cipla won the Dun & Bradstreet American Express Corporate Awards in 2006.
In 2007, Forbes included Cipla in the 200 'Best under a Billion' list of best small Asian companies.
In 2012, Cipla received the Thomson Reuters India Innovation Award.
In 2014, Economic Times Lifetime Achievement Award.
In 2015, Cipla stood third in India's Most Reputed Brands (Pharmaceutical) list.
APR 2020-21 Certified great place to work

ABOUT INVEST YADNYA

Invest Yadnya is a company that educates and simplifies the concepts of personal finance for each individual. We have amalgamated technology with financial planning expertise to help an individual meet their financial objectives. We invest time, money, and knowledge to build financial literacy in India.

We offer various products and services including, Personalized Financial Planning, Stock Market Analysis with eBook Subscriptions, Simplest Income Tax Information Bank, Comprehensive Mutual Fund Reviews, and Do-It-Yourself Financial Planning.


Invest Yadnya should be a choice because it offers unbiased and transparent stock analysis reports. Our work is knowledge-based and has specific proprietary methodologies and a stock research framework. We continuously keep updating our data and have the latest information available. 


We help our clients do extensive research on 950+ companies, including fundamental CIPLA stock analysis. You can find the latest CIPLA stock price on Invest Yadnya. We also provide our clients with the Cipla balance sheet. It helps the clients understand the financial position of the company before making any investment decisions. The Cipla stock analysis helps the investors identify the intrinsic worth of the security. Cipla results provide a summary of how the business incurs revenues and expenses. We also offer our clients with the Cipla share price graph.


Detailed Stock Articles on Cipla vs DRL Stock Comparison: Part 1 & Part 2 are provided on our website, which offers an in-depth Cipla stock review. It gives an investor a sense of whether the company is growing, stable or deteriorating. This helps investors make a viable investment decision with a thorough discussion on Cipla annual report & Cipla research report.

Invest Yadnya offers numerous resources for Cipla share analysis. With the available Cipla financial statements, price chart, ratios, etc., get a detailed analysis of the company. With Invest Yadnya’s available resources, get an overview of the company, both from the qualitative and financial perspective. With Cipla financial statement analysis, the investors shall make a viable investment decision depending on your risk profile & other economic factors.

The Cipla analysis gives the clients a better understanding of the company’s EPS, Debt-Equity Ratio etc. It helps clients take the first step in choosing which companies to invest in. 

The ratio analysis of Cipla overall helps allocate the equity in the Portfolio of an investor to add to its favourable returns.

To find the Cipla Performance analysis & Cipla stock chart, subscribe to our Equity Research and Stock Fundamental Analysis Tool, Stock-O-Meter.

Our website has information about 113 other Pharmaceuticals & Drugs companies that give insight into its financials. Companies include Divis Laboratories, Dr Reddy's Laboratories, Sun Pharmaceutical Industries, Biocon, Aurobindo Pharma, Lupin, Torrent Pharmaceuticals, Cadila Healthcare, Abbott India, Glaxosmithkline Pharmaceuticals & many more.



Brands Of Cipla

Comment

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya